Entropy Neurodynamics

Entropy Neurodynamics Net Debt / EBITDA

The Net Debt to EBITDA of Entropy Neurodynamics (ENP.AX) as of Oct 30, 2026 is 0.44. In the previous year, Net Debt to EBITDA was 1.08 — a change of -59.25% (lower).

Net Debt / EBITDA

0.44

YoY

-59.25%

Last updated:

Net Debt to EBITDA of Entropy Neurodynamics is 2025 0.44 . Net Debt to EBITDA of Entropy Neurodynamics was 2024 1.08 . It decreases by -59.25% lower compared to the previous year.

The Entropy Neurodynamics Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2020
0.10 AUD
Jan 1, 2021
0.97 AUD
Jan 1, 2022
0.09 AUD
Jan 1, 2023
0.01 AUD
Jan 1, 2024
1.08 AUD
Jan 1, 2025
0.44 AUD
The Entropy Neurodynamics Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
0.44-59.25%
1.08+7,716.75%
0.01-84.46%
0.09-90.86%
0.97+840.16%
0.10—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entropy Neurodynamics Stock analysis

What does Entropy Neurodynamics do? Entropy Neurodynamics Ltd develops and commercializes exosomes as therapeutic agents. The company holds intellectual property related to exosome technology and offers LEAP manufacturing, LOAD API loading, and EVPS tropism technologies. Pharmaceutical and biotechnology companies purchase these proprietary technologies to enhance their own exosome-based products. The firm invests in biopharmaceutical drug development and leverages its portfolio of know-how to support partners in exosome medicine development. Exopharm Ltd. is the company's brand name, and it operates through its exosome technology portfolio. The firm's technologies solve key challenges in exosome medicine success, including manufacturing efficiency and targeted delivery. Biopharmaceutical companies are the primary buyers of these technologies, seeking to integrate exosome delivery systems into their therapeutic pipelines. The company's business model centers on licensing its exosome-related IP and know-how to pharmaceutical and biotech firms. By providing LEAP, LOAD API, and EVPS technologies, Entropy Neurodynamics enables partners to overcome technical barriers in exosome-based drug development. This approach generates revenue through technology licensing agreements with industry partners. Entropy Neurodynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entropy Neurodynamics stock

Net Debt to EBITDA of Entropy Neurodynamics is 0.44 in 2025.

Net Debt to EBITDA of Entropy Neurodynamics changed from 1.08 to 0.44, representing a -59.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Entropy Neurodynamics since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Entropy Neurodynamics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Entropy Neurodynamics

All Key Metrics — Entropy Neurodynamics